Benzinga  Apr 8  Comment 
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the presentation of data from a study demonstrating the anti-tumor effects and...
StreetInsider.com  Mar 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/Piper+Jaffray+Upgrades+ZIOPHARM+Oncology+%28ZIOP%29+to+Neutral/9242350.html for the full story.
StreetInsider.com  Mar 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/ZIOPHARM+Oncology%2C+Inc.+%28ZIOP%29+Posts+Q4+Loss+of+9cShare/9238505.html for the full story.
SeekingAlpha  Dec 15  Comment 
By Manny Backus: The War On Cancer It is hard to believe that 43 years have passed since President Richard Nixon declared "War on Cancer". It was December of 1971 when President Nixon signed the National Cancer Act into law, declaring, "I...
Benzinga  Dec 7  Comment 
ZIOPHARM Oncology (Nasdaq: ZIOP) today announced positive interim results from its ongoing Phase 1/2 study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate that is being evaluated with the oral activator, veledimex, in patients with...
Benzinga  Dec 6  Comment 
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced the unanimous approval of the National Institutes of Health's Recombinant DNA Advisory Committee (RAC) for the initiation of a Phase 1 study of Ad-RTS-IL-12, an adenoviral vector engineered to...
StreetInsider.com  Dec 6  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ZIOPHARM+Oncology+%28ZIOP%29+Receives+NIH+RAC+Approval+for+Ad-RTS-IL-12+Phase+1/8954466.html for the full story.
TheStreet.com  Nov 1  Comment 
span.style4 {font-size: 10px; font-weight: bold; } span.style5 {font-size: 10px} By Jonathan Moreland, founder of Insider Insights and author of Profit From Legal Insider Trading. NEW YORK (TheStreet) -- It is a victory for common...
Benzinga  Oct 22  Comment 
ZIOPHARM Oncology (NASDAQ: ZIOP) today announced that it intends to commence an underwritten public offering of $50,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by ZIOPHARM. J.P. Morgan...
Benzinga  Oct 22  Comment 
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the discovery and development of new cancer therapies, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the presentation of a...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki